AstraZeneca plc Rating Reiterated by Credit Suisse (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by Credit Suisse in a research note issued on Thursday. They currently have a GBX 4,800 ($80.52) price objective on the stock. Credit Suisse’s price target would suggest a potential upside of 17.03% from the stock’s previous close.
AZN has been the subject of a number of other recent research reports. Analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 3,700 ($62.07) price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Monday. They now have a GBX 4,500 ($75.49) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “underweight” rating on shares of AstraZeneca plc in a research note on Friday, August 8th. They now have a GBX 3,700 ($62.07) price target on the stock. Six equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 4,055.48 ($68.03).
AstraZeneca plc (LON:AZN) opened at 4093.9998 on Thursday. AstraZeneca plc has a 52-week low of GBX 3086.50 and a 52-week high of GBX 5750.00. The stock has a 50-day moving average of GBX 4335.04 and a 200-day moving average of GBX 4195.. The company’s market cap is £51.707 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.